DSpace at RU >

Browsing by Author Eggermont, A.M.M.

Full Text	Issue Date	Title	Author(s)
	2012	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.	Eggermont, A.M.M.; Suciu, S.; Testori, A.; Kruit, W.H.; Marsden, J., et al
	2012	20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.	Deroose, J.P.; Eggermont, A.M.M.; Geel, A.N. van; Wilt, J.H.W. de; Burger, J.W., et al
	2012	Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series.	Pool, A.E. van der; Damhuis, R.A.; Ijzermans, J.N.M.; Wilt, J.H.W. de; Eggermont, A.M.M., et al
	2011	Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection	Ploeg, A.P. van der; Akkooi, A.C. van; Schmitz, P.I.M.; Geel, A.N. van; Wilt, J.H. de, et al
	2011	Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.	Prens, S.P.; Ploeg, A.P. van der; Akkooi, A.C. van; Montfort, C.A. van; Geel, A.N. van, et al
	2011	Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases	Deroose, J.P.; Grunhagen, D.J.; Geel, A.N. van; Wilt, J.H. de; Eggermont, A.M.M., et al
	2011	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)	Patel, P.M.; Suciu, S.; Mortier, L.; Kruit, W.H.; Robert, C., et al
	2011	Long-Term Results of Tumor Necrosis Factor {alpha}- and Melphalan-Based Isolated Limb Perfusion in Locally Advanced Extremity Soft Tissue Sarcomas	Deroose, J.P.; Eggermont, A.M.M.; Geel, A.N. van; Burger, J.W.; Bakker, M.A. den, et al
	2010	Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases.	Pool, A.E. van der; Wilt, J.H.W. de; Lalmahomed, Z.S.; Eggermont, A.M.M.; Ijzermans, J.N.M., et al
	2010	Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000.	Pool, A.E. van der; Lalmahomed, Z.S.; Wilt, J.H.W. de; Eggermont, A.M.M.; Ijzermans, J.N.M., et al
	2010	Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.	Bouwhuis, M.G.; Suciu, S.; Testori, A.; Kruit, W.H.; Sales, F., et al
	2009	Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.	Etten, B. van; Wilt, J.H.W. de; Brunstein, F.; Eggermont, A.M.M.; Verhoef, C.
	2009	Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.	Bottomley, A.; Coens, C.; Suciu, S.; Santinami, M.; Kruit, W., et al
	2009	The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.	Verhoef, C.; Pool, A.E. van der; Nuyttens, J.J.; Planting, A.S.; Eggermont, A.M.M., et al
	2009	Total pelvic exenteration for primary and recurrent malignancies.	Ferenschild, F.T.; Vermaas, M.; Verhoef, C.; Ansink, A.C.; Kirkels, W.J., et al
	2009	Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.	Bouwhuis, M.G.; Suciu, S.; Collette, S.; Aamdal, S.; Kruit, W.H., et al
	2009	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).	Fusi, A.; Collette, S.; Busse, A.; Suciu, S.; Rietz, A., et al
	2009	Abdominosacral resection for locally advanced and recurrent rectal cancer.	Ferenschild, F.T.; Vermaas, M.; Verhoef, C.; Dwarkasing, R.S.; Eggermont, A.M.M., et al
	2009	Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy.	Pool, A.E. van der; Lalmahomed, Z.S.; Wilt, J.H.W. de; Eggermont, A.M.M.; Ijzermans, J.M., et al
	2009	Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities	Grunhagen, D.J.; Wilt, J.H.W. de; Geel, A.N. van; Verhoef, C.; Eggermont, A.M.M.
	2007	Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.	Schmidt, H.; Suciu, S.; Punt, C.J.A.; Gore, M.; Kruit, W., et al
	2006	Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.	Horssen, R. van; Rens, J.A.; Brunstein, F.; Guns, V.; Gils, M. van, et al
	2006	EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.	Horssen, R. van; Rens, J.A.; Schipper, D.; Eggermont, A.M.M.; Hagen, T.L.M. ten
	2006	TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.	Horssen, R. van; Hagen, T.L.M. ten; Eggermont, A.M.M.
	2006	Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay.	Horssen, R. van; Galjart, N.; Rens, J.A.; Eggermont, A.M.M.; Hagen, T.L.M. ten
	2006	Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.	Punt, C.J.A.; Suciu, S.; Gore, M.; Koller, J.; Kruit, W., et al
	2006	Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.	Horssen, R. van; Eggermont, A.M.M.; Hagen, T.L.M. ten
	2005	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.	Eggermont, A.M.M.; Suciu, S.; MacKie, R.; Ruka, W.; Testori, A., et al
	2005	Hereditary breast cancer growth rates and its impact on screening policy.	Tilanus-Linthorst, M.M.; Kriege, M.; Boetes, C.; Hop, W.C.J.; Obdeijn, I.M., et al
	2005	Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.	Keilholz, U.; Punt, C.J.A.; Gore, M.; Kruit, W.; Patel, P., et al
	2004	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.	Kleeberg, U.R.; Suciu, S.; Bröcker, E.B.; Ruiter, D.J.; Chartier, C., et al
	2004	Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.	Brouckaert, P.; Takahashi, N.; Tiel, S.T.; Hostens, J.; Eggermont, A.M.M., et al
	1997	Recombinant interleukin-2 based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group	Keilholz, U.; Stoter, G.J.; Punt, C.J.A.; Scheibenbogen, C.; Lejeune, F.J., et al
	1997	Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan	Borel Rinkes, I.H.M.; Vries, M.R. de; Jonker, A.M.; Swaak, A.J.G.; Hack, C.E., et al
	1997	Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group	Keilholz, U.; Goey, S.H.; Punt, C.J.A.; Proebstle, T.M.; Salzmann, R., et al
	1996	Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma. A histopathological, immunohistochemical and electron microscopical study	Nooijen, P.T.G.A.; Manusama, E.R.; Eggermont, A.M.M.; Schalkwijk, C.J.M.; Stavast, J., et al
	1996	Transient induction of E-selectin expression following TNF-alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific	Nooijen, P.T.G.A.; Eggermont, A.M.M.; Verbeek, M.M.; Schalkwijk, C.J.M.; Buurman, W.A., et al
	1996	Synergistic antitumor effect of recombinant human tumor necrosis factor alpha with melphalan in isolated limb perfusion in the rat	Manusama, E.R.; Nooijen, P.T.G.A.; Stavast, J.; Durante, M.M.; Marquete, R.T., et al
	1996	Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma	Kruit, W.H.J.; Punt, C.J.A.; Goey, S.H.; Mulder, P.H.M. de; Gratama, J.W., et al
	1995	Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study	Goey, S.H.; Eggermont, A.M.M.; Punt, C.J.A.; Slingerland, R.; Gratama, J.W., et al
	1995	VWF release and platelet aggregation in human melanoma after perfusion with TNFalpha	Renard, N.; Nooijen, P.T.G.A.; Schalkwijk, C.J.M.; Waal, R.M.W. de; Eggermont, A.M.M., et al
	1995	Vwf Release and Platelet-Aggregation in Human-Melanoma after Perfusion with Tnf-Alpha	Renard, N.; Nooijen, B.T.G.A.; Schalkwijk, L.; Dewaal, R.M.W.; Eggermont, A.M.M., et al